Edesa Biotech Stock Net Income
| EDSA Stock | USD 2.38 0.06 2.46% |
Edesa Biotech fundamentals help investors to digest information that contributes to Edesa Biotech's financial success or failures. It also enables traders to predict the movement of Edesa Stock. The fundamental analysis module provides a way to measure Edesa Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Edesa Biotech stock.
Edesa |
Edesa Biotech Company Net Income Analysis
Edesa Biotech's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Edesa Biotech Net Income | (6.17 M) |
Most of Edesa Biotech's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Edesa Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Edesa Biotech reported net income of (6.17 Million). This is 101.81% lower than that of the Biotechnology sector and 108.81% lower than that of the Health Care industry. The net income for all United States stocks is 101.08% higher than that of the company.
Edesa Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Edesa Biotech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Edesa Biotech could also be used in its relative valuation, which is a method of valuing Edesa Biotech by comparing valuation metrics of similar companies.Edesa Biotech is currently under evaluation in net income category among its peers.
Edesa Fundamentals
| Return On Equity | -1.51 | ||||
| Return On Asset | -0.74 | ||||
| Current Valuation | 15.73 M | ||||
| Shares Outstanding | 6.99 M | ||||
| Shares Owned By Insiders | 9.29 % | ||||
| Shares Owned By Institutions | 25.98 % | ||||
| Number Of Shares Shorted | 852.08 K | ||||
| Price To Earning | (3.96) X | ||||
| Price To Book | 13.06 X | ||||
| Price To Sales | 120,478 X | ||||
| Gross Profit | 311.2 K | ||||
| EBITDA | (6.13 M) | ||||
| Net Income | (6.17 M) | ||||
| Cash And Equivalents | 12.81 M | ||||
| Cash Per Share | 0.83 X | ||||
| Total Debt | 19.87 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 2.68 X | ||||
| Book Value Per Share | 0.37 X | ||||
| Cash Flow From Operations | (4.89 M) | ||||
| Short Ratio | 0.02 X | ||||
| Earnings Per Share | (1.87) X | ||||
| Target Price | 19.0 | ||||
| Number Of Employees | 16 | ||||
| Beta | 0.77 | ||||
| Market Capitalization | 17.06 M | ||||
| Total Asset | 3.81 M | ||||
| Retained Earnings | (58.59 M) | ||||
| Working Capital | (157.21 K) | ||||
| Current Asset | 6.92 M | ||||
| Current Liabilities | 581.49 K | ||||
| Net Asset | 3.81 M |
About Edesa Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Edesa Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Edesa Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Edesa Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Edesa Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Edesa Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Edesa Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Edesa Biotech Stock:Check out Edesa Biotech Piotroski F Score and Edesa Biotech Altman Z Score analysis. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. If investors know Edesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edesa Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edesa Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Edesa Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.